Cefiderocol
To view the entire topic, please log in or purchase a subscription.
Pediatrics Central™ is an all-in-one application that puts valuable medical information, via your mobile device or the web, in the hands of clinicians treating infants, children, and adolescents. Explore these free sample topics:
-- The first section of this topic is shown below --
INDICATIONS
FDA
- Patients ≥18 y/o for the treatment of the following infections caused by susceptible Gram-negative microorganisms:
- Complicated urinary tract infections (cUTI), including pyelonephritis
- Hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP)
NON-FDA APPROVED USES
- MDR GNR (e.g. Pseudomonas, Acinetobacter, CRO) infections when no other alternatives are available
-- To view the remaining sections of this topic, please log in or purchase a subscription --
INDICATIONS
FDA
- Patients ≥18 y/o for the treatment of the following infections caused by susceptible Gram-negative microorganisms:
- Complicated urinary tract infections (cUTI), including pyelonephritis
- Hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP)
NON-FDA APPROVED USES
- MDR GNR (e.g. Pseudomonas, Acinetobacter, CRO) infections when no other alternatives are available
There's more to see -- the rest of this entry is available only to subscribers.